Previous studies have indicated the focal presence of growth factors and focal low levels of cell proliferation in human atherosclerotic plaques. Using human carotid plaques and an antibody to platelet-derived growth factor (PDGF)-A chain, we have begun to assess growth factor significance by spatially correlating growth factor gene expression with actual cell proliferation. Since PDGF is a mitogen for smooth muscle and related cells and since inflammatory cells (eg, macrophages) can also proliferate in these lesions, it was important to exclude inflammatory cell proliferation from this consideration. Therefore, we have used a triple immunolabeling approach, combining the above anti-PDGF-A chain antibody with an inflammatory cell cocktail (CD68+CD45 for monocyte/macrophages and lymphocytes) and adding an anti-proliferating cell nuclear antigen (PCNA) antibody to mark proliferating cells. In the carotid atherosclerotic plaques, PDGF immunostaining was distributed focally, preferentially in the fibrous cap and vascularized regions, and was present in P5 revious studies from this laboratory and others have indicated the focal presence of growth factors (eg, platelet-derived growth factor [PDGF])1,2 and focal low levels of cell proliferation3 in human atherosclerotic plaques. Yet none have tried to verify growth factor significance by spatially correlating growth factor with actual cell proliferation within the plaque. Using human carotid plaques and an antibody to PDGF-A chain, we have begun such studies. Since PDGF is a mitogen for smooth muscle and related mesenchymal cells45 and since inflammatory cells (eg, macrophages) can also proliferate in these lesions,3 it was important for us to exclude inflammatory cell proliferation from this consideration. Therefore, we have used a triple immunolabeling approach combining the above anti-PDGF-A antibody with an anti-proliferating cell nuclear antigen (PCNA) antibody to identify proliferating cells, together with either a smooth muscle a-actin antibody or an inflammatory cell antibody cocktail (CD68+CD45 for monocyte/macrophages and lymphocytes). We have then sought to determine whether PDGF-A immunostaining is correlated with noninflammatory mesenchymal cell proliferation (which is presumably smooth muscle derived, but we
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Materials and Methods

Tissue Preparation
We studied samples of advanced, complicated, human carotid artery plaques removed at the time of endarterectomy surgery. As control arterial tissue, portions of human internal mammary artery left over from coronary bypass surgery were obtained. The final study set consisted of 13 carotid plaques and 11 internal mammary arteries. These studies were approved by the Human Subjects Review Committees, both at the University of Michigan, Ann Arbor, and at the University of Washington, Seattle, the institutional sources of these tissue samples. Specimens were fixed overnight in methanol-Carnoy's fixative (methanol: chloroform: glacial acetic acid in a 60:30:10 volume ratio), decalcified in 2% L-ascorbic acid for 3 days, paraffinembedded, and sectioned at 5 -,m thickness. Depending on the size of the sample, one to three cross sections of artery were thus placed in each tissue block (ie, one block per patient), from which several serial sections were generated for hematoxylin and eosin staining and for the subsequent immunocytochemistry studies.
Immunocytochemistry Reagents
As a marker of cell proliferation, an anti-PCNA antibody was used (PC10, DAKO Corp). To visualize PDGF-A, we used a polyclonal rabbit anti-human PDGF-AA antibody (UBI). This antibody specifically reacts with PDGF-AA and -AB by Western blotting (UBI, personal communication) and has been shown to give strong and specific immunostaining on formalin-fixed paraffin-embedded material, staining that can be blocked by preadsorbing with purified PDGF-A; the immunostaining patterns of this antibody correlate well with in situ mRNA hybridization for PDGF-A.6 The cell-type specific antibodies used on these tissues were as follows: an antismooth muscle a-actin antibody (Boehringer Mannheim Corp) to identify smooth muscle cells, CD68 (DAKO-CD68, KP1, DAKO) to identify macrophages, and anti-human leukocyte common antigen (DAKO-LCA, CD45RB, DAKO) for lymphocytes and monocytes. Biotinylated horse anti-mouse and goat anti-rabbit antibodies, avidin-biotin-peroxidase complex (ABC), alkaline phosphatase-conjugated streptavidin, normal (nonimmune) horse and goat sera, alkaline phosphatase substrate kits (red and blue), and biotin solution (from an avidin-biotin-blocking kit) were obtained from Vector Laboratories. Normal mouse and rabbit sera were provided by Immunon. 3',3'-Diaminobenzidine was obtained from Sigma Chemical Co, and Histoclear, a clearing agent, was from National Diagnostics. Recombinant PDGF-AA and -BB protein was provided by Promega.
Triple-Label Immunostaining
Sections were deparaffinized, and endogenous peroxidase activity was blocked with H202 for 5 minutes. With 2% normal horse serum used as a diluent, the PC10 antibody (dilution, 1:1000) was applied overnight at 4°C. The secondary antibody incubation (biotinylated horse anti-mouse antibody; dilution, 1:1000) was for 3 hours at 4°C, followed by avidin-biotin amplification (ABC kit) for 30 minutes. Incubation with 0.1% 3',3'-diaminobenzidine, H202, and 8% nickel chloride at 37°C for 10 minutes produced a black reaction product. After the first immunostaining procedure, the sections were washed copiously in phosphate-buffered saline (PBS), incubated with normal mouse serum (dilution, 1:10) for 15 minutes at room temperature, washed again, incubated with biotin solution for 15 minutes at room temperature, dehydrated in graded ethanols, cleared in Histoclear, and air-dried. After rehydration, the second primary antibody (rabbit anti-human PDGF-AA antibody at 1:500 dilution in 2% normal goat serum) was applied overnight at 4°C. The biotinylated secondary antibody to the second primary antibody (biotinylated goat anti-rabbit antibody at 1:500 dilution in 2% normal horse serum) was then applied for 3 hours at 4°C, incubated for another 30 minutes in streptavidin-alkaline phosphatase (diluted at 1:1000), and then developed with the alkaline phosphatase substrate, which produced a red reaction product. After the second immunostaining procedure, the sections were washed copiously in PBS, incubated with biotin solution for 15 minutes at room temperature, dehydrated in graded ethanols, cleared in Histoclear, and air-dried (similar to the first procedure). After rehydration, the third primary antibody or antibody cocktail was applied overnight at 4°C. In each case, one slide was incubated with anti-smooth muscle a-actin antibody (diluted at 1:200 in 2% normal horse serum); another slide, with the "inflammatory cell cocktail," consisted of two antibodies: CD68 (1:500 dilution in 2% normal horse serum) and CD45 (1:40 dilution). The biotinylated secondary antibody to the second primary antibody (biotinylated horse anti-mouse antibody at 1:500 dilution in 2% normal goat serum) was then applied for 3 hours at 4°C, incubated for another 30 minutes in streptavidin-alkaline phosphatase (diluted at 1:1000), and then developed with the alkaline phosphatase substrate, which produced a blue reaction product. Methyl green counterstain was used to visualize nuclei in the tissue sections.
To avoid cross-reactivity between the first primary antibody (PCNA) and third primary antibodies (CD45/CD68 or smooth muscle a-actin), which were both mouse monoclonal antibodies, the dehydration and drying steps between immunoreactions above were introduced. This approach is adapted from Wang and Larsson,7 who reported that the use of formaldehyde fixation, dehydration, and drying of the sections between the immunoreactions of the first and second primary antibod-ies could minimize or even eliminate such cross-reactivity. Presumably, this alters the first primary antibody in a way that is not recognized by subsequently applied anti-mouse antibodies. We found empirically that dehydration and drying alone were sufficient for the combination of antibodies we used.
Control Studies
We recognize the unusual complexity of triple-labeling procedures in terms of potential cross-reactivity between the numerous immunoreagents involved. Special attention was therefore paid to the positive and negative controls, which included controls for the individual antibodies as well as overall controls for the whole triple-labeling technique.
PCNA Control
We have previously performed numerous PCNA immunostainings on different tissues with excellent reproducibility. Our protocol has provided stable cell numbers over a range of antibody dilutions, and the 1:1000 dilution provides the best signal-to-background staining ratio. As previously described with a different PCNA antibody,3 "in-house" studies with the current antibody have revealed a good correlation with thymidine labeling of rat intestine, and the rat intestine control tissue is run with each PCNA immunostaining run and always reveals specific nuclear staining localized to the crypt epithelium of the intestinal mucosa (data not shown). Human tonsil was also used as a control tissue and gave positive staining primarily in the follicular centers, as expected. Using a different proliferation-specific antibody to Ki-67 antigen,8 we have also obtained very similar levels and patterns of staining on both human carotid plaques and tonsil tissue (data not shown).
Additional control immunoreactions on this tissue included the use of normal mouse serum, which gave no staining.
Tissue Controls for the Cell Type-Specific Antibodies
As a positive tissue control for a-actin, rat intestine was used with every run and gave the expected well-localized pattern within tunica muscularis, with negative staining of epithelial elements and fibroblasts (data not shown). Human tonsil and spleen were similarly used as controls for all cell type-specific antibodies. a-Actin staining was mostly concentrated around the blood vessels, CD68-positive cells demonstrated typical macrophage localization and morphology, CD45-positive cells mostly demonstrated lymphocyte-like appearance, and some macrophages were also stained (data not shown).
PDGF Control
The immunostaining of the anti-PDGF-AA antibody was completely blocked by a 10-fold molar excess of the recombinant human PDGF-AA protein. Other negative controls for immunocytochemistry consisted of the use of nonimmune rabbit serum instead of the primary antibody. We also designed artificial control tissues. We ran dot blots9 first, to be sure that the antibody can recognize recombinant AA protein without any chemical modifications, and the antibody also did not cross-react with recombinant PDGF-B chain. Since the PDGF-AA blot was definitely positive and the PDGF-BB blot was negative, it was reasonable to raise the following question: Can the same antibody recognize the protein after certain chemical and thermal modifications, such as fixation and paraffin embedding? To achieve this aim, we reconstituted the recombinant PDGF-AA protein in a 7.5% solution of gelatin (final concentration of the protein, 50 gg/mL), injected this solution into the lumen of methacarn-fixed rat aorta, sealed this "sausage," and then used it as a regular piece of tissue; ie, it was fixed in methacarn, emnbedded, etc. Then we ran immunostaining with the anti-PDGF-AA antibody on the cross sections of aorta and demonstrated immunostainable material in the aortic lumen. The analogous experiment with the PDGF-BB-filled aorta, as well as with unmodified gelatin, demonstrated no immunoreactivity (Fig 1) . 
Control of Triple-Label Procedure
Triple labeling was performed at the same time with single labeling using each individual antibody (ie. PCNA. PDGF-AA, a-actin, CDS6, CD45, and the mixture of the latter two) on the serial sections. For every specimen, patterns of individual antibody immunoreactions on triple-labeled slides corroborated the patterns of their single-labeled counterparts. Additionally. the various antibodies used (all IgGs) served as nlonspecific IgG-staining controls for each other. and each provided distinctly different colors and patterns (eg, smooth muscle versus macrophage distributions) and. except for the PCNA antibody. did not give nuclear localizations.
Morphometric Analysis
To quantitatively correlate the distribution of PCNA-positive cells with immunostainable PDGF-A, a microscopic fieldby-field analysis was performed. The triple-labeled tissue sections were studied by light microscopy at x400 magnification using the Image 1 system of computer color image analysis (Universal Imaging Corp). Contiguous nonoverlapping microscopic fields were analyzed covering the whole tissue on the slide, and each field was scored as follows: (1) number of PCNA-positive nuclei unassociated with CD68+CD45-positive cytoplasm (e. proliferating noninflammatorv cells). (2) PDGF-A immunostainable area (area occupied by red alkaline phosphatase immunoreaction product), (3) location in intima or media. (4) location in the fibrous cap, (5) location in a foam cell-rich area, and (6) presence of microvessels. Variables 3 through 6 were scored on a present (1) or absent (0) basis. To determine what plaque features are the best predictors of mesenchymal cell proliferation, we performed both logistic regression and multiple linear regression analyses using the microscopic field-by-field data sets. We combined all of the microscopic field data from all 13 carotid plaques into one large data set. We recognize that the above pooling of field-by-field data sets assumes that each microscopic field is an independent event, even if separate fields come from the same plaque. Since we were concerned that this assumption might not be valid. separate identification variables for each plaque were also included. These were assigned as follows: IDI. carotid plaque from patient 1: ID2. carotid plaque from patient 2; etc; with the plaque from patient 13 being indicated by IDI through ID12, all having a value of 0. To determine predictors of the presence versus absence of PCNA within a microscopic field, immunostainable PCNA in noninflammatory cells in a given microscopic field was coded as a yes/no variable and used as the outcome variable. The remaining independent variables for each microscopic field were as listed above.
To obtain an independent statistical confirmation on the spatial relation between the presence of PCNA-positive non-inflammatory cells and the presence of PDGF (on the yes/no basis), we used the X test on the same pooled set of microscopic fields.
To determine predictors of the number of proliferating mesenchymal cells, multiple linear regression was performed with the number of PCNA-positive nininflammatory cells per microscopic field used as the outcome variable. All microscopic field data from all 13 carotid plaques were pooled into one data sample. The independent variables (defined above) were the microscopic field presence/absence of the following: foam cells, location in the fibrous cap, plaque microvessels, appearance in the media. and immunostainable PDGF-A. Because of multiple colinearity problems, we were not able to include the specimenidentification variables in this particular analysis.
We also used a subset of this pooled data set from the 13 carotid plaques to look at fields containing immunoreactivity for either PDGF-A or noninflammatory PCNA (most fields contained no immunostain). Spearman's rank correlation coefficient was generated to study the correlation between a number of PCNA-positive noninflammatorY cells and the PDGF A immunostainable area.
Statistical analysis was performed by using the statistical package TRUE EPISTAT (Epistat Services).
Results
General Observations
For the purposes of the present study, we operationally defined "mesenchymal cell" to refer to any cell not marking with the inflammatory cell markers used (CD45 or CD68). The vast majority (>95%c) did not line vascular spaces and thus were not endothelial cells. We also realize that modulated smooth muscle cells may no longer be positive for smooth muscle markers, and this leaves open the possibility that some negative (mesenchymal) cells may even have non-smooth muscle lineages.
Internal mammary arteries were uniformly negative for PCNA in intimas and medias (Fig 2a) . In the human carotid plaque specimens, very few PCNA-positive nuclei were seen (generally, 1t to 3% of nuclei). As we reported earlier,5 the majority of them were inflammatory cells (Fig 2b) . Among PCNA-positive noninflammatory cells. a-actin-positive cells were detected very rarely (<5%c of either the PDGF-A-positive or noninflammatory PCNA-positive cells). However, triple labeling for PCNA, PDGF-A, and CD68+CD45 revealed some noninflammatory cell proliferation in every carotid plaque studied. Positive cells were often randomly located as single cells with occasional clusters. On the basis of visual impressions, the majority of PCNApositive noninflammatory cells were concentrated in the intima. Within the intima, we found more positive cells in the vascularized regions (Fig 2c) . Internal mammary arteries were also uniformly negative for PDGF-A immunoreactivity (Fig 2a) . In the carotid plaques, 22.2%c of microscopic fields contained PDGF-immunostainable material. We found that PDGF-A was distributed focally, preferentially in the fibrous cap region but also in vascularized and foam cell-rich regions. PDGF-A immunostaining appeared in two distinct patterns: cytoplasmic (Fig 2c and 2d ) and diffuse extracellular (Fig 2b) staining. Both immunostaining patterns could be competed out by preadsorbing the PDGF-A antiserum with purified human recombinant PDGF-A protein. In the vascularized regions, only occasional endothelial-appearing cells displayed PDGF-A positivity. More often, the signal could be found in cells adjacent to the endothelium in the capillary wall or in mesenchymal-appearing intimal cells (Fig 2c) . Some (but not all) of those cells expressed a-actin (Fig 2d) . At the same time, cytoplasmic PDGF-A staining never colocalized with inflammatory markers (Fig 2b and 2c) .
PCNA nuclear staining combined with PDGF-A cytoplasmic staining of the same cell was detected extremely rarely (< 1 c of PCNA-positive cells). PDGF-A staining was detected more frequently than noninflammatory PCNA positivity. In general, triple immunolabeling revealed three types of immunoreactive patterns: microscopic fields containing only PCNA-positive noninflammatory cells, microscopic fields containing only PDGF-A, and fields containing both. It was impossible to evaluate qualitatively what type of fields predominated.
Quantitative Analyses of Colocalizations Within the Same Microscopic Fields
The above and present analyses were based on studying 78 to 218 microscopic fields per plaque (average, 117 fields per plaque). These field data are briefly summarized in Table 1 . In spite of lack of obvious visual spatial PCNA indicates proliferating cell nuclear antigen; PDGF, platelet-derived growth factor. All of the microscopic field data from all 13 carotid plaques were classified according to immunostainable PDGF-A status (+ or -) and noninflammatory PCNA status (+ or -) and are presented here as the number of microscopic fields per sample, which fell into each PDGF/PCNA category.
correlations between PDGF-A localization and mesenchymal cell proliferation, X2 analysis ( Table 2) revealed that the presence of PCNA-positive noninflammatory cells and the presence of PDGF within the same microscopic fields were strongly positively correlated (x2=116.38, P<.000001, odds ratio=6.63). As can be seen from this table, many more microscopic fields were PDGF-A positive than were PCNA positive, although the majority of PCNA-positive fields were PDGF-A positive.
For an analysis of noninflammatory cell proliferation by plaque topographical features, all of the microscopic field data from all carotid plaques were pooled and analyzed first by logistic regression, with the presence/ PCNA indicates proliferating cell nuclear antigen; PDGF, platelet-derived growth factor. All of the microscopic field data from all 13 carotid plaques were classified according to immunostainable PDGF-A status (+ or -) and noninflammatory PCNA status (+ or -) and are pooled to generate the above contingency PDGF indicates platelet-derived growth factor; PCNA, proliferating cell nuclear antigen. All microscopic field data from all 13 carotid plaques were pooled into one data sample. Thus, a total of 1588 fields were analyzed. The outcome variable was the presence or absence of at least one PCNA-positive noninflammatory cell in a field and was coded on a yes/no basis. The independent variables (defined in "Materials and Methods") correlated with this outcome variable are listed above, with the calculated regression coefficients, associated odds ratios, and statistical P values of each to the overall regression analysis. In addition, specimen identity variables were also included as described in "Materials and Methods," with ID1 referring to fields from carotid sample 1, ID2 referring to fields from carotid sample 2, etc. The overall regression statistics are as follows: X2=31 1.3735, df=16, and P=.0000. The comparison of this model with the actual data obtained (using all variables with the above coefficients to predict the outcome variable) shows that the model accounts for 35.67% of the log likelihood, a goodness of fit x 2=32.1734, df=6, P=.0000, and a correct classification of the outcome variable of 92.7% given a cutoff probability of 0.5. absence of immunostainable PCNA in each microscopic field being the outcome variable. The overall logistic regression model provided a good fit to the data, correctly classifying 92.7% of microscopic fields if a cutoff predicted probability (of presence) of 0.5 was used. Of all of the independent microscopic field variables noted (presence of: microvessels, foam cells, fibrous cap location, location within the intima, PDGF-A, and sample-specific identifiers), only two variables, (1) the presence of microvessels and (2) immunostainable PDGF-A, were significant positive predictors, as indicated by values of P<.05 and odds ratios of >4. These data are summarized in Table 3 . Of note is that vascularity appears to be a considerably better predictor of PCNA positivity than immunostainable PDGF-A (odds ratios= 16.4 and 5.3, respectively). Finally, plaque identity had no apparent effect on these correlations. Only one plaque (ID2) appeared to have a much smaller significant, independent, albeit negative, association <.0001 PDGF indicates platelet-derived growth factor. All microscopic field data from all 13 carotid plaques were pooled into one data sample. Thus, a total of 1588 fields were analyzed. The outcome variable was the number of proliferating noninflammatory cells per microscopic field. The independent variables (defined in "Materials and Methods") were the microscopic field presence/ absence of the following: foam cells, location in the fibrous cap, plaque microvessels, appearance in the media, and immunostainable PDGF-A. These are listed with their calculated coefficients, SEM, and P value of significance to the overall regression. Because of multiple colinearity problems, we were not able to include the specimen identification variables in this particular analysis.
with noninflammatory cell proliferation in our logistic regression analysis (odds ratio=0.1159; P<.05; see Table 2).
The above logistic regression analysis indicates likelihoods of finding at least one PCNA-positive noninflammatory cell per microscopic field but says nothing about the number of positive cells found. To assess this, multiple linear regression was performed on these same pooled carotid plaque fields by using the number of PCNA-positive noninflammatory cells per field as the quantitative outcome variable. Vascularity and immunostainable PDGF-A presence are still highlighted as significant variables. Vascularity again appears to be a better predictor of PCNA positivity than immunostainable PDGF-A (coefficients of 0.776 versus 0.178). However, this regression model accounts for only 22.36% of the PCNA variation seen ( Table 4 ).
The above-described x2 logistic regression and multiple linear regression analyses, using all studied microscopic fields, all indicated a significant spatial association between immunostainable PDGF-A and cell proliferation. However, to determine if more PDGF-A in a field means more proliferation within the same field, we then considered only those microscopic fields that were positive for either PCNA or PDGF-A and pooled all such fields from all carotid plaques. This . I allowed us to graph the number of PCNA-positive noninflammatory cells versus PDGF-A immunostainable area per field. This graph did not suggest any significant "dose-response" correlation ( Fig 3) . If anything, Spearman's correlation on these data revealed r= -.32 and P<.000001, ie, a negative correlation. Thus, the previously indicated positive spatial correlations are at least partly due to the observation that the vast majority of microscopic fields in this human carotid plaque material are devoid of either proliferative activity or immunostainable PDGF-A chain. Thus, in general, topographic features, particularly microvessels and PDGF-A presence, are good predictors of the plaque regions containing PCNA-positive noninflammatory cells but appear less able to account for the number of PCNA-positive noninflammatory cells in our admittedly crude "dose-response" analysis.
Discussion
Our triple-label immunocytochemical studies have indicated the focal presence of PDGF-A and focal low levels of noninflammatory cell proliferation in human carotid atherosclerotic plaques. According to the quantitative analyses, PDGF-A and localization in vascularized areas are good predictors of the noninflammatory cell proliferation within the same microscopic fields.
We found that PDGF-A was present in two distinct patterns: cytoplasmic and diffuse extracellular. Since both patterns of anti-PDGF-AA immunostaining were completely blocked by an excess of the recombinant PDGF-AA protein, we believe that they represent a true pattern of this growth factor distribution in human atherosclerotic plaques rather than a nonspecific artifact of the immunocytochemical procedure. Such extracellular immunostainable PDGF-A could conceivably be derived from previously organized thrombi or hemorrhages or be derived from previously injured or dead vascular cells (eg, similar to the presumed origin of extracellular basic fibroblast growth factor). Biochemical data also suggest that PDGF-A can bind to extracellular (as well as cell-associated) heparan-sulfate proteoglycan. 10 Cytoplasmic PDGF-A staining never colocalized with inflammatory markers (CD68 and CD45) within the same cells. Rare PDGF-A-positive endothelial cells and mesenchymal-appearing intimal cells (with or without simultaneous a-actin expression) were the only cellular source of immunostainable PDGF-A positivity. At the same time, PCNA nuclear staining combined with PDGF cytoplasmic staining of the same cell was FIG 3. Graph showing correlation between the number of proliferating noninflammatory cells (per microscopic field) and area (square micrometers) occupied by platelet-derived growth factor (PDGF)immunostainable material (Spearman's r=-.3223, two-tailed P<.0001). PCNA indicates proliferating cell nuclear antigen. detected extremely rarely (<5% of either the PDGF-Apositive or noninflammatory PCNA-positive cells). We recognize that positive spatial correlations do not prove causality between a particular growth factor and cell proliferation. However, taking all of the above into consideration and the statistically significant tendency for PDGF-A-and PCNA-positive noninflammatory cells to colocalize in the same fields, our data support the hypothesis of PDGF-A playing a significant role in promoting cell proliferation in human atherosclerosis. Our data also suggest that PDGF-A is most likely involved with mesenchymal cell proliferation in a paracrine fashion, since proliferation and PDGF-A expression in the same cell were extremely rare. To the best of our knowledge, this is the first direct demonstration of PDGF-A in relation to such cell proliferation in human atherosclerosis. However, it is not surprising, since at least in animal models of mechanical injury-induced intimal proliferation, the PDGF-A gene is expressed by intimal smooth muscle cells in the areas with the highest proliferative activity.11'12 This is also one of the first genes among growth factor genes that is switched on as an immediate response of smooth muscle cells to mechanical injury.13 According to our logistic and linear regression analyses, the best predictor of appearance of PCNA-positive noninflammatory cells in human carotid plaques is a location in vascularized fields. Since it is known that at least PDGF-A mRNA is often in the same fields (which we demonstrated earlier on the mRNA level using in situ hybridization2 and in the present study on the protein level), it seems reasonable to raise the following question: Can mesenchymal cell proliferation in vascularized areas solely depend on PDGF-A? We would suggest a negative answer because (1) multiple logistic regression findings identify microvessels to be independent and stronger predictors of PCNA staining than PDGF-A immunoreactivity and (2) there are a few microvessels with PCNA-positive cells but without PDGF-A immunostaining. Therefore, vascularized regions likely contain other stimuli of cell proliferation. This may include other growth factors such as PDGF-B, which was also highlighted in such microvessels in our previous in situ hybridization studies.2 Alternatively, the presumed better oxygenation and nutrient delivery in vascularized versus avascular plaque regions might also be expected to be growth promoting.
PDGF-A immunostainable protein itself is a good independent predictor of mesenchymal cell proliferation, although it is a weaker predictor compared with vascularization. However, PDGF-A expression seems neither necessary nor sufficient for such individual cell proliferation, since PDGF-positive fields were usually PCNA negative, and some PCNA-positive PDGF-Anegative fields were also detected. Furthermore, the "dose-response curve analogue" (the relation between PDGF-A-immunostainable area and a number of PCNA-positive noninflammatory cells) is negative. There are several possible reasons why we did not detect a perfect quantitative correlation between PDGF-A and such noninflammatory cell proliferation: (1) PDGF-A is probably not the only important growth-promoting factor in this tissue, as evidenced by our higher independent correlations with plaque mi-interferon-y) may be important and nonuniformly distributed in this complex tissue. (2) We do not know if all of the mesenchymal cells in PDGF-A-positive fields are capable of responding to this PDGF-A in terms of appropriate receptor expression and active signal transduction pathways. Future studies of PDGF receptor expression in this tissue are planned. (3) The PDGF-A antibody used detects PDGF-A antigen but conceivably is not specific for biologically active PDGF-A in all areas of the plaque. For example, endogenous proteases in this material might partially degrade some PDGF-A but still allow it to be immunoreactive. (4) Finally, our actual measurement of the "area of immunostainable PDGF" is at best a crude measure, which is probably not linearly quantitative with respect to activity, given the vagaries of immunostaining intensities and the above discussion. For these and other reasons, the spatial association analyses (X2 and logistic regression) are probably the most important and are supported by our linear regression test, which indicated that the presence (if not the amount) of PDGF-A was positively correlated with the number of proliferating noninflammatory cells per field. Therefore, we feel that our data suggest that PDGF-A plays some growth-promoting role in these human plaques but that other factors are also at play and, similar to the presence of microvessels, may be more important for noninflammatory cell proliferation.
Our observations corroborate abundant in vitro data demonstrating that PDGF-AA per se is a weak stimulator of smooth muscle cell proliferation but that it exerts an additive effect in combination with other growth stimuli (basic fibroblast growth factor, PDGF-BB, etc).'14,l Moreover, PDGF-AA can be induced by external growth stimuli (transforming growth factor-f3, low-density lipoprotein, and thrombin).1416-20 Therefore, PDGF-A may play a very important (but not a solo) role in a finely tuned orchestra of the mesenchymal cell proliferation-related factors.
Finally, as proposed by Barrett and Benditt,21 PDGF may have an important nonmitogenic maintenance function in the atherosclerotic plaque. 21 It has also been shown in animal experiments and in vitro that certain stimuli can upregulate PDGF-AA expression in smooth muscle cells without the induction of cell replication. 22, 23 However, our data are consistent with a suggested role of PDGF-A as a "mild" stimulator of mesenchymal cell proliferation in human atherosclerotic plaques. This might be of real biological significance, since even "indolent" proliferation can cause a stenosis in decades.
Additionally, every newly formed mesenchymal cell can be a source of collagen and other extracellular matrix protein synthesis, another important aspect of atherosclerotic plaque growth.24 Further use of this novel triple-labeling methodology might help to screen other growth factor(s) potentially responsible for cell proliferation in human atherosclerosis. study. We also thank Bascom Brown for his technical assistance in tissue processing and sectioning.
